Injective Price Surges on Canary ETF Filing, $7 Resistance in Sight

Injective's price surged nearly 10% after Canary Capital's proposed staked INJ ETF filing, which has strengthened the long-term investment case for the token.

The latest filing provides greater regulatory clarity, institutional custody solutions, and staking mechanisms that differentiate Injective from other Layer-1 networks.

Institutional interest in Injective is growing, with investors shifting their attention to blockchain networks with strong fundamentals and real-world utility.

The proposed ETF, trading under the ticker INJS, would allow investors to gain exposure to both the token's price performance and staking income.